U s Stem Cell Inc (USRM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access USRM Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding U s Stem Cell Inc's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2022)
(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent0.01
Cash & Short-term Investments0.00
Accounts receivable0.00
Inventories0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.06
Total Current Assets0.07
Other Assets, Noncurrent0.00
Total Assets0.07
Liabilities
Accounts Payable, Current AC1.62
Accrued Liabilities, Current2.58
Short-term Debt2.58
Other Liabilities, Current7.29
Deferred Revenue, Current DE0.00
Total Current Liabilities14.08
Long-term debt0.68
Total Long-term Debt0.68
Deferred Revenue, Noncurrent DE0.05
Other liabilities, Noncurrent0.00
Deposit Liability Current0.47
Total Liabilities14.81
Stockholders' Equity
Common Stock Value0.63
Additional Paid In Capital Common Stock127.14
Retained Earnings / Accumulated Deficit-142.52
Other Equity0.00
Common Stockholder's Equity-14.75
Total Stockholder's Equity-14.75
Liabilities & Stockholder's Equity0.07
4 historic quarters locked

Sign in to unlock the full U s Stem Cell Inc balance sheet history.

About U s Stem Cell Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001185185-23-000339

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.